“Never stop dreaming, never stop believing, never give up, never stop trying, and never stop learning.” We'll come back stronger... #kualalumpurrovers# #klrovers# #LigaM3# #afl# #playforthecity#

NEXT!!!! Our first home match, we meet NAGA UKS FC this coming Sunday, 19 March 2023, 4.45 pm. This time our venue is Stadium UPM, Serdang. See you GUYS!!!! #kualalumpurrovers# #klrovers# #LigaM3# #afl# #playforthecity#

MEDICAL REPORT First-team player Roony Bardghji has successfully undergone surgery for a rupture of the anterior cruciate ligament in his right knee. The procedure took place at the Hospital de Barcelona and was performed by Dr. Joan Carles Monllau, under the supervision of the Club's Medical Services.

🚨 Carlos Baleba doubtful for start of new campaign through injury. 22yo Brighton & Hove Albion midfielder suffered ankle ligament damage in pre-season - expected to spend period on sidelines but longer-term problem not anticipated by #BHAFC# @TheAthleticFC

Breaking: Minnesota Timberwolves star Anthony Edwards has sustained a bone bruise and hyperextension in his left knee and is expected to miss multiple weeks, sources tell @ShamsCharania. Results showed Edwards avoided any ligament damage, but he will now miss time.

Ryan Gosling might just be the luckiest man in the world… In 2024, Ryan Gosling surprised Jeopardy! viewers by appearing in a special video clue tied to his upcoming sci-fi film Project Hail Mary, based on Andy Weir’s bestselling novel. Instead of delivering a typical Hollywood-themed question, Gosling presented a clue involving science and medicine, fitting nicely with the movie’s scientific themes. The clue centered on the ACL, or anterior cruciate ligament, and Gosling’s characteristically dry delivery made the unexpected appearance even more entertaining. Viewers were amused by the sight of the Hollywood star casually explaining a medical term before a contestant quickly supplied the correct response. The unusual combination of celebrity promotion, science trivia, and Gosling’s understated humor quickly attracted attention online. What could have been an ordinary promotional appearance became a memorable Jeopardy! moment, blending the show’s educational format with a little unexpected Hollywood comedy.

Today, for the first time, an FDA advisory panel voted to open a legal path for BPC-157 — the most sought-after peptide in the world. That's genuinely a milestone. And it's worth understanding exactly what just happened. The panel voted 8-6 to recommend adding BPC-157 to the list of substances licensed compounding pharmacies can prepare under a real prescription. FDA staff had recommended against it. The panel went the other way. Here's why I think that matters, even as a cautious physician. Right now, millions of people are already taking this. They're buying research-grade powder from anonymous overseas sellers, mixing it on a kitchen counter, and injecting it. Over 40% of gray-market samples fail purity testing. No dosing standards. No sterility guarantee. No adverse-event reporting. No physician watching. A vote like today's is the first real step toward moving all of that into daylight — into licensed pharmacies, with quality control, physician oversight, and traceable safety data. That's a genuine win for patient safety, regardless of what you believe about the molecule. And the underlying science is legitimately exciting. BPC-157 is a synthetic peptide modeled on a protective protein found in human gastric juice. Hundreds of animal studies show accelerated tendon and ligament healing, gut protection, anti-inflammatory effects, and angiogenesis — the growth of new blood vessels. The preclinical signal is strong enough that serious researchers keep coming back to it. That's not nothing. That's why the demand exists in the first place. Now the sober part, because you deserve both halves. The published human evidence is still remarkably thin — roughly 30 subjects in the strongest studies, with the longest treatment lasting about two weeks. And the routes actually studied barely overlap with how people use it today. There are no completed randomized controlled trials for the popular uses. Also worth knowing: today's vote is not FDA approval. It's advisory and non-binding. Formal rulemaking takes 12 to 24 months. Nothing changed legally today. My one clinical caution, and it comes from my own field: the same angiogenesis that may heal a tendon is a signal that says grow. Nobody has studied that over years, and nobody has studied it in cancer survivors. Worth a real conversation with your doctor before you assume it's harmless. But here's the encouraging part. A Phase 2 hamstring trial is already underway. A regulated pathway means better product, real prescriptions, and — crucially — actual data collection instead of anecdotes. This is how a gray market becomes medicine: oversight first, then evidence, then answers. Today was a step in that direction. Now let's get the trials done and find out what this thing can really do.